HTB homepage • Conference reports • Articles by subject • Subscribe September 2003 Contents Editorial Volume 4 Number 7 August/September 2003 Treatment alerts EMEA public statement on early virologic non-response in patients with HIV infection treated with tenofovir in combination with lamivudine and abacavir Conference reports XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, 10-14 June 2003 Transmission of drug resistance – at 11% in Europe and 17% in the UK HIV coinfection, reinfection and superinfection Single-dose nevirapine resistance in over 75% of mothers Transmission of drug resistant virus does not revert to wild-type and does not appear ‘less fit’ Standard genotype assays may miss 75% of mutations when present in less than 35% of plasma sample Low-level resistance and minority populations: cross resistance between nevirapine and efavirenz occurs even in the absence of genotypic mutations found using population sequencing Persistent effect of d4T and 3TC, but not NNRTIs in the presence of associated genotypic mutations Replicative capacity results complicated by minority wild-type virus Tenofovir, resistance and K65R and concomitant nucleosides Response to STI is determined by virus rather than immunological response Why resistance rarely develops with viral suppression <50 copies/mL Long-term persistence of distinct mutations in genital tract 5th International Workshop on Adverse Drug Reactions and Lipodystrophy, 8-11 July 2003, Paris Underlying mechanisms: adipocytes and cytokines More mitochondrial DNA depletion IMT and cardiovascular risk Reduced bone mineral density in HIV-positive women Rosiglitazone with insulin resistance Additional benefits of exercise with metformin Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir Facial fat loss – measuring and treatment Uridine treatment for mitochondrial toxicity Breast enlargement in men and testosterone treatment Severe efavirenz psychotic events Treatment interruption: a real choice 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July 2003, Paris Nevirapine and MTCT: the single-dose backlash Triple nucleoside combinations fail patients again Nucleoside-sparing regimens Dual boosted PIs in salvage therapy BMS reports on atazanavir efficacy and safety in treatment experienced patients Unsupervised treatment interruptions are associated with increased risk of AIDS or death Uridine as a potential treatment for NRTI related mitochondrial toxicity Long term exposure to nucleoside analogues and peripheral nerve function Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy First results from ESPRIT study: CD4 response to IL-2 is associated with higher nadir and baseline CD4 and younger age Lessons learned from early HAART in acute HIV infection CD4 cell reconstitution is significantly slower in older patients Pharmacology studies at the 2nd IAS conference Studies highlight problems of rectal disease in HIV-positive patients Antiretrovirals T-20 launched in UK US approval of FTC (emtricitabine) Treatment access Appointment of industry executive to supervise US AIDS initiative provokes criticism Guidelines US guidelines updated (July 2003) Side effects Bone mineral metabolism and HIV-infection Coinfections and complications Protease inhibitors and Kaposi’s sarcoma (KS): KS relapse seen after switch from PI to NNRTI Drug resistance Resistance summary of new PIs: atazanavir and tipranavir Other news UK highest rate of new infections at over 5,000 cases Medicines Control Agency slated by Commons committee On the web Conference reports and abstracts Medscape articles Newletters and reports PDFs Volume 4 Number 7 August/September 2003 PDF HTB homepage • Conference reports • Articles by subject • Subscribe
